Physician profile
Mark L Greaves
NPI 1518139914
$2,010.47
in general payments reported to CMS, 2019-2025
16 companies · $737 in 2025
The $737 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68.62 · 2020: $196 · 2021: $225 · 2022: $234 · 2023: $227 · 2024: $323 · 2025: $737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,245 · Long Term Medical Supply Or Device Loan: $42.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,244.64 |
| Long Term Medical Supply Or Device Loan | $42.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $449.67 | 2021-2025 | |
| Janssen Biotech, INC. | $416.59 | 2019-2025 | Tremfya, Stelara |
| Genzyme Corporation | $278.72 | 2023-2025 | |
| Pfizer INC. | $148.49 | 2020-2022 | |
| Boston Scientific Corporation | $124.51 | 2025 | General - Hemostasis |
| Phathom Pharmaceuticals, INC. | $124.09 | 2025 | Voquezna |
| Novo Nordisk INC | $117.76 | 2025 | Wegovy |
| Lilly USA, LLC | $113.04 | 2024 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $46.90 | 2019-2023 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.33 | 2021-2022 | |
| Pentax of America, INC. | $42.38 | 2024 | Endo Stratus Co2 Insufflator |
| Ironwood Pharmaceuticals, INC | $31.18 | 2020-2024 | |
| Ethicon US, LLC | $23.18 | 2021 | |
| Ardelyx, INC. | $22.20 | 2023 | Ibsrela |
| Endo Pharmaceuticals INC. | $14.71 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $13.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Greaves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.